| Schedule of information regarding reportable segments |
| | | | | | | | | | | | | | | Three Months | | Nine Months | For the Periods Ended March 31 | | 2026 | | 2025 | | 2026 | | 2025 | Net sales | | | | | | | | | | | | | Animal Health | | $ | 291,225 | | $ | 258,377 | | $ | 864,658 | | $ | 670,318 | Mineral Nutrition | | | 73,418 | | | 66,774 | | | 205,351 | | | 189,086 | Performance Products | | | 18,900 | | | 22,674 | | | 51,337 | | | 58,114 | Total segments | | $ | 383,543 | | $ | 347,825 | | $ | 1,121,346 | | $ | 917,518 |
| | | | | | | | | | | | | | | Three Months | | Nine Months | For the Periods Ended March 31 | | 2026 | | 2025 | | 2026 | | 2025 | Animal Health | | | | | | | | | | | | | Net sales | | $ | 291,225 | | $ | 258,377 | | $ | 864,658 | | $ | 670,318 | Cost of sales | | | 176,315 | | | 166,221 | | | 517,218 | | | 412,547 | Selling, general and administrative expenses(1) | | | 54,935 | | | 46,133 | | | 154,385 | | | 131,513 | Add: Depreciation and amortization | | | 11,128 | | | 11,369 | | | 34,310 | | | 29,318 | Add: Acquisition-related cost of goods sold(2) | | | — | | | 1,708 | | | 1,956 | | | 3,342 | Add: Phibro Forward income growth initiatives implementation costs - cost of goods sold (3) | | | — | | | 3,798 | | | — | | | 3,798 | Add: Phibro Forward income growth initiatives implementation costs - SG&A (3) | | | — | | | 1,771 | | | — | | | 1,771 | Subtract: Insurance proceeds(4) | | | — | | | (1,546) | | | (1,177) | | | (2,803) | Adjusted EBITDA | | | 71,103 | | | 63,123 | | | 228,144 | | | 161,684 | | | | | | | | | | | | | | Mineral Nutrition | | | | | | | | | | | | | Net sales | | | 73,418 | | | 66,774 | | | 205,351 | | | 189,086 | Cost of sales | | | 66,838 | | | 59,562 | | | 185,337 | | | 169,804 | Selling, general and administrative expenses(1) | | | 1,987 | | | 1,974 | | | 5,606 | | | 5,611 | Add: Depreciation and amortization | | | 548 | | | 524 | | | 1,623 | | | 1,555 | Adjusted EBITDA | | | 5,141 | | | 5,762 | | | 16,031 | | | 15,226 | | | | | | | | | | | | | | Performance Products | | | | | | | | | | | | | Net sales | | | 18,900 | | | 22,674 | | | 51,337 | | | 58,114 | Cost of sales | | | 14,693 | | | 17,491 | | | 40,657 | | | 45,258 | Selling, general and administrative expenses(1) | | | 2,237 | | | 2,124 | | | 6,743 | | | 6,245 | Add: Depreciation and amortization | | | 249 | | | 277 | | | 716 | | | 902 | Adjusted EBITDA | | | 2,219 | | | 3,336 | | | 4,653 | | | 7,513 | | | | | | | | | | | | | | Adjusted EBITDA – Total segments | | $ | 78,463 | | $ | 72,221 | | $ | 248,828 | | $ | 184,423 | Reconciliation of Adjusted EBITDA to income before income taxes: | | | | | | | | | | | | | Less: | | | | | | | | | | | | | Interest expense, net | | | 10,431 | | | 9,355 | | | 34,246 | | | 25,992 | Depreciation and amortization – Total segments | | | 11,925 | | | 12,170 | | | 36,649 | | | 31,775 | Depreciation and amortization – Corporate | | | 523 | | | 446 | | | 1,520 | | | 1,419 | Corporate costs | | | 17,662 | | | 17,335 | | | 58,105 | | | 50,706 | Acquisition-related cost of goods sold(2) | | | — | | | 1,708 | | | 1,956 | | | 3,342 | Acquisition-related transaction costs | | | 130 | | | 636 | | | 581 | | | 12,875 | Stock-based compensation expense - named executive officer awards granted in fiscal year 2024 | | | 179 | | | 179 | | | 538 | | | 538 | Phibro Forward income growth initiatives implementation costs - cost of goods sold (3) | | | — | | | 3,798 | | | — | | | 3,798 | Phibro Forward income growth initiatives implementation costs - SG&A(3) | | | 3,391 | | | 3,980 | | | 7,026 | | | 6,026 | Insurance proceeds(4) | | | — | | | (1,546) | | | (3,786) | | | (2,803) | Foreign currency losses (gains), net | | | 1,909 | | | (5,528) | | | 6,988 | | | 6,609 | Income before income taxes | | $ | 32,313 | | $ | 29,688 | | $ | 105,005 | | $ | 44,146 |
| (1) | Selling, general and administrative expenses primarily include compensation-related expenses for employees not directly involved in the production and sale of inventory, rent expenses, research and development costs, marketing expenses, and other general and administrative expenses. |
| (2) | Represents cost of goods sold related to the stepped-up value of inventory obtained in acquisitions. |
| (3) | Phibro Forward is a company-wide initiative focused on unlocking additional areas of revenue growth and cost savings. For the three and nine months ended March 31, 2026, this includes $3.4 million and $7.0 million, respectively, recorded within selling, general and administrative expenses primarily for consultancy costs related to the initiative. For the three and nine months ended March 31, 2025, this includes $5.3 million for non-cash asset write-offs, of which $3.8 million was recorded within cost of goods sold, and $1.5 million was recorded within selling, general and administrative expenses, related to the closure of an immaterial business within the Animal Health segment. |
| (4) | Represents insurance settlement gains, which are recorded within selling, general and administrative expenses. |
|